Add BrightSurf on Google Email

Meta-analysis shows targeted radiation therapy may be as effective as standard care for small cell lung cancer patients with brain metastases

A meta-analysis published in The Lancet Oncology suggests that targeted radiation therapy, which spares healthy brain tissue, is equitable to whole brain radiation therapy for patients with small cell lung cancer and brain metastases. This approach may improve their care experience with fewer negative cognitive consequences.

SourceSt. Michael's Hospital·JournalThe Lancet Oncology·TypeMeta-analysis·DateMay 27, 2022

HKU biologists reveal a novel macrophages-mediated mechanism that promotes peritoneal metastasis of ovarian cancer, providing important insights into its therapeutic strategy

Researchers at HKU have discovered a novel cellular and molecular interaction between cancer cells and tumour-associated macrophages that promote peritoneal metastasis of ovarian cancer. The study reveals that Wnt/b-catenin signalling upregulates the expression of metadherin, which communicates with macrophages through CEACAM1.

SourceThe University of Hong Kong·JournalAdvanced Science·DateMay 16, 2022

ASTRO issues clinical guideline on radiation therapy for brain metastases

The new ASTRO guideline provides guidance on radiation therapy for brain metastases, including evidence-based recommendations for multidisciplinary planning and delivery of advanced techniques to manage intact and resected brain tumors. The guideline aims to improve quality of life and outcomes for patients with brain metastases.

SourceAmerican Society for Radiation Oncology·JournalPractical Radiation Oncology·TypeLiterature review·DateMay 10, 2022

Getting sticky with it: Phospholipid found to play a key role in epithelial cell adhesion

Researchers found phosphatidylinositol bisphosphate (PIP2) essential for epithelial cell-cell adhesion and maintaining cellular identity. PIP2 regulates epithelial properties by recruiting Par3 to the plasma membrane, facilitating the formation of adherens junctions and preventing epithelial-mesenchymal transformation.

SourceTokyo University of Science·JournalNature Communications·TypeExperimental study·DateMay 9, 2022

Tracing a cancer’s family tree to its roots reveals how tumors grow

A team of researchers used a CRISPR-based approach to study the evolution of lung cancer cells, tracking their history from the first activation of cancer-causing mutations. The study revealed significant diversity between subpopulations of cells within the same tumor, with certain groups becoming more fit and aggressive over time.

SourceWhitehead Institute for Biomedical Research·JournalCell·TypeExperimental study·DateMay 5, 2022

Brain metastasis looking back in the mirror

Researchers created patient-derived models of brain metastases that recapitulate human disseminated disease, reflecting clinical manifestations and biological characteristics. These models can be used to test therapeutic value of different treatments and explore new approaches tailored to each patient.

SourceInstituto de Medicina Molecular·JournalCell Reports Medicine·TypeExperimental study·DateMay 3, 2022

Mount Sinai researchers discover how early-stage breast cancer can become a silent killer in some patients

Researchers at Mount Sinai have discovered a previously unknown mechanism by which not-yet-malignant breast cancer cells can travel to other organs and 'turn on' to become metastatic. The study identified potential diagnostic biomarkers, including the transcription factor NR2F1, that could help predict relapse.

An international consortium, led by IRB Barcelona and the biotechnology company Merus, reports the discovery of MCLA-158, the first clinical candidate screened in organoids targeting cancer stem cells of solid tumors

Researchers from IRB Barcelona and Merus have discovered MCLA-158, a bi-specific antibody targeting cancer stem cells. The treatment prevents metastasis and slows primary tumor growth in experimental models of cancer.

SourceInstitute for Research in Biomedicine (IRB Barcelona)·JournalNature Cancer·TypeExperimental study·DateApr 25, 2022

Breast cancer: Why metastasis spreads to the bone

A team of biologists identified a protein involved in the spread of breast cancer to bones. The discovery confirms the importance of cellular plasticity during the metastatic process and could lead to new treatments. ZEB1, a protein that increases cell plasticity, was found to direct cells with metastatic characteristics to bones.

SourceUniversité de Genève·JournalNature Communications·TypeNews article·DateApr 21, 2022

Lockdown for tumour cells

A novel inhibitor has been discovered that stalls a critical enzyme inside tumour cells, locking them in place and preventing invasion into healthy tissue. The findings hold promise for the development of metastasis-blocking agents.

SourceUniversity of Konstanz·JournalCell Chemical Biology·DateApr 20, 2022

Scientists discover gene mutation that signals aggressive melanoma

Researchers have identified a gene mutation in ARID2 that signals the development of aggressively metastatic melanoma. The study suggests patients with this mutation may require different treatment approaches to manage their cancer effectively. Further research is underway to refine this understanding and improve patient outcomes.

HKUMed discovers new molecular mechanism in promoting melanoma angiogenesis and metastasis, paving the way for new therapeutic opportunities

A research team at LKS Faculty of Medicine, The University of Hong Kong, has discovered a new molecular pathway governing melanoma angiogenesis and metastasis. They found that the expression of DEPDC1B is significantly associated with poor patient survival and positively correlated with melanoma growth and metastasis.

SourceThe University of Hong Kong·JournalAdvanced Science·DateApr 4, 2022

Getting fuel to an invading cell's front line

Researchers have identified two glucose transporters that disrupt the energy supply to invading worm cells and stop them in their tracks. By deactivating these genes, glucose and ATP levels dropped, and worm cells stalled their spread. This discovery could lead to new ways to cut off cancer cells' fuel lines and prevent metastasis.

SourceDuke University·JournalDevelopmental Cell·TypeExperimental study·DateMar 22, 2022

CNIO researchers design a drug screening platform compatible with patient biopsies to fight metastasis

Researchers have designed METPlatform, a drug screening platform compatible with patient biopsies, to investigate patients' own tumour tissue. The platform has identified new therapeutic targets and biomarkers for aggressive brain metastases, suggesting HSP90 inhibitors as potential treatments.

SourceCentro Nacional de Investigaciones Oncológicas (CNIO)·JournalEMBO Molecular Medicine·DateFeb 17, 2022

Immune cells leave fingerprints on tumors metastasized to the brain offering clues to future therapies

Scientists analyzed over 100,000 cells from 15 human brain metastases and identified two functional archetypes of metastatic cells, each containing both immune and non-immune cell types. These archetypes work together within single cells to shape inflammatory and proliferative processes co-existent in each metastatic tumor.

SourceUniversity of California San Francisco Medical Center·JournalCell·TypeExperimental study·DateFeb 8, 2022

CHOP researchers define a 3-tiered molecular classification of pediatric differentiated thyroid cancer, where fusion oncogenes predict the most invasive behavior

Researchers at Children's Hospital of Philadelphia define a 3-tiered molecular classification system for pediatric differentiated thyroid cancer, where fusion oncogenes are associated with more invasive disease and lower remission rates. The study contrasts findings from adults, who have a two-tiered system based on BRAF mutations.

SourceChildren's Hospital of Philadelphia·JournalJournal of Clinical Oncology·DateJan 31, 2022

Antibody with engineered peptide targets bone metastasis

Researchers at Rice University and Baylor College of Medicine have created an antibody with an engineered peptide that effectively targets and attacks bone tumors in breast cancer. The study shows the therapeutic efficacy is best when a moderate amount of the drug compound is delivered, offering new hope for treating bone metastases.

SourceRice University·TypeExperimental study·DateJan 24, 2022